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of cure. In contrast to that, if they noticed the symptoms in 
themselves, as much as 5% of medical students and 9% of 
students of other schools would seek medical advice only 
when they made everyday functioning impossible. 
 
Conclusion: The level of HNC cancer knowledge among young 
population is alarmingly low. A large number of students of 
non-medical schools and universities are unaware of its risk 
factors and early symptoms. This group would benefit from 
increasing the number of educational campaigns, which 
would lead to earlier presentation, diagnosis and treatment 
of HNC. 
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Purpose or Objective: The aim of this study was to evaluate 
the parotid glands toxicity and its relationship with the dose 
in a cohort of head and neck cancer patients treated with 
IMRT. 
 
Material and Methods: 78 patients out of 110 treated in our 
department between January 2011 and October 2015 were 
included in the analysis. Criteria to select patients were: at 
least 6 months follow up, the omo-lateral parotid (OP) close 
to the high (HR) and / or intermediate (IR) risk CTV. 
Characteristics of the studied patients population are shown 
in Table1.The GTV, whenever present, CTV HR (regions at 
high risk of microscopic disease), CTV IR (regions at 
intermediate risk) and CTV LR (regions at low risk) were 
contoured on each slice. The targets were expanded 3 mm to 
obtain the PTVs. The prescribed dose was 66-70 Gy (2 – 2.13 
Gy /fr) to PTV HR, 59.4 – 66 Gy (1.8 – 2 Gy/fr) to PTV IR; 
56.1Gy (1.7 Gy/fr) to PTV LR. IMRT with Simultaneous 
Integrated Boost (SIB) technique was used (41patients were 
treated with Tomotherapy and 36 with VARIAN 21EX). The OP 
and the CP were contoured; PTV SV1 OP and SV2 CP were 
defined as overlapping volumes of PTVs and glands. Priority 
was given to PTV when OP was partially included. The dose 
limit (Dmean) was <= 25 Gy to the whole contralateral gland 
(if not close to GTV N) and < 24 Gy to the volume of CP not 
included in the PTV (external CP). Salivary gland toxicity was 
assessed weekly, during RT, and at 3,6,9,12,18,24 months 
after RT and was graduated using the RTOG toxicity scale. 
 
 
 
Results: The dose delivered to the PTVs was 67.9 Gy (range 
66-70) 2.02 Gy/fr (1.9 -2.2) to PTV HR, 62.3 Gy (range 58-66) 
1.86 Gy/fr (1.7-2) to PTV IR, 55.9 Gy (range 51-60) 1.68 Gy/fr 
(1.65-2) to PTV LR. The mean dose was 41.56 Gy (range 17.8 
- 66.8) to OP and 24.9 Gy (range 4.7-39.7) to CP; the external 
CP received 21.7 Gy mean dose. 36 (46.1%) patients 
experienced mouth dryness, thickened saliva and altered 
taste (31 G1 and 5 G2) during RT. At a median follow up of 24 
months (range 6-56.2) 19 cases with xerostomia were 
recorded, 15 (19%) G1 and 4 (5,1%) G2. No G3 was observed. 
The symptom was recorded on an average of 8 months (range 
6-15) after RT. Only 13/36 patients with acute salivary 
problems experienced late xerostomia. 
 
Conclusion: In our experience 25 Gy mean dose to the whole 
contra-lateral parotid, with <24 Gy mean dose to the 
external CP, even with sacrifice of the OP, allowed our 
patients to maintain an adequate salivation. 24% of cases 
experienced G1 and G2 xerostomia. No G3 toxicity was 
observed. 
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Purpose or Objective: Recent studies show that low activity 
(1.1GBq) of RAI is as effective as high activity (3.7GBq) in 
treating those with low-intermediate-risk differentiated 
thyroid cancer (DTC). The purpose of our study was to 
retrospectively review post-operative I131 uptake and 
ablation rates in those with DTC. 
 
Material and Methods: Data was obtained from St. Luke’s 
Radiation Oncology Network (SLRON) patient registry. 
Selection criteria included histologically proven DTC; post-
thyroidectomy; pre and post RAI ablation scan and RAI 
ablation in SLRON. There were 68 cases of DTC treated with 
RAI identified between 2005-2007 that were suitable for 
analysis and met criteria and follow up of ≥5 years 
 
Results: Of the cases analysed 73% were female and 27% 
male with a mean age of 44 years. The predominant 
histological subtype was papillary (73%), followed by 
follicular (22%). Most had early stage disease; Stage I (65%), 
Stage II (22%), Stage III (13%), 39 cases were pN0 and 29 had 
pN1 disease. Regarding surgery performed 39 patients had a 
complete excision CE, 22 had residual disease and there was 
no information for 7 cases. Thirty seven (37) cases had 
microscopically positive margins, 26 were negative and it was 
unknown in 5. Pre RAI ablation, Post op. RAI (I131) uptake in 
these patients was an average of 3.6 % in pN1 disease and 
5.1% in those with pN0 disease. The max uptake was 28%. The 
extent of the surgery tended to influence the trend of 
uptake. There was a trend to a higher mean uptake in those 
who didn’t have a CE with an uptake of 0.1-17%, and mean of 
6.3%. Patients that had a CE had an uptake of 0-28%, and 
mean of 3.9%. In the SLRON there was no standard protocol 
for RAI dosage at the time the patients were treated The 
mean and range of doses of RAI administered was looked at 
based on pre-ablation uptake scans. Group 1 had a pre-
ablation uptake of <4% and group 2 >4%. For group 1 the 
mean dose was 3.9GBq with a range 2.2-7.4GBq, and group 2 
had a mean of 3.7GBq with a range of 2.8-7.4GBq. Post-
ablative RAI131 scans showed an average of 0.07% uptake 
with the majority of patients (33) having <0.1% uptake. At 
the time of analysis 23 patients remained disease free, 10 
had metastases (M1) and 2 had died from metastatic disease.  
 
Conclusion: In those that received RAI ablation, high ablation 
rates ≥90% were shown despite variability in post -op. I131 
uptake and dose of RAI administered. There didn’t appear to 
be an association between those with recurrent or metastatic 
disease and their pre-ablation uptake rates, it was more 
associated with original stage.  
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